| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.01M | 6.48M | 10.88M | 22.24M | 24.29M | 115.53M | 25.1M | 48.73M | 68.7M |
| Revenue Growth % | - | -0.08% | 0.68% | 1.04% | 0.09% | 3.76% | -0.78% | 0.94% | 0.41% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 7.01M | 6.48M | 10.88M | 22.24M | 24.29M | 115.53M | 25.1M | 48.73M | 68.7M |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | -0.08% | 0.68% | 1.04% | 0.09% | 3.76% | -0.78% | 0.94% | 0.41% |
| Operating Expenses | 15.2M | 28.34M | 58.8M | 109.44M | 134.11M | 154.91M | 87.41M | 92.46M | 94.86M |
| OpEx % of Revenue | 2.17% | 4.37% | 5.4% | 4.92% | 5.52% | 1.34% | 3.48% | 1.9% | 1.38% |
| Selling, General & Admin | 6.1M | 8.02M | 13.67M | 27.03M | 36.05M | 39.67M | 41.28M | 39.09M | 35.3M |
| SG&A % of Revenue | 0.87% | 1.24% | 1.26% | 1.22% | 1.48% | 0.34% | 1.64% | 0.8% | 0.51% |
| Research & Development | 9.1M | 20.32M | 45.12M | 82.42M | 98.06M | 115.24M | 46.12M | 53.38M | 59.56M |
| R&D % of Revenue | 1.3% | 3.13% | 4.15% | 3.71% | 4.04% | 1% | 1.84% | 1.1% | 0.87% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.83M | -21.97M | -47.91M | -87.2M | -109.83M | -39.38M | -62.31M | -43.74M | -26.16M |
| Operating Margin % | -1.26% | -3.39% | -4.4% | -3.92% | -4.52% | -0.34% | -2.48% | -0.9% | -0.38% |
| Operating Income Growth % | - | -1.49% | -1.18% | -0.82% | -0.26% | 0.64% | -0.58% | 0.3% | 0.4% |
| EBITDA | -8.19M | -20.54M | -45.56M | -81.89M | -100.02M | -29.18M | -53.3M | -35.48M | -21.59M |
| EBITDA Margin % | -1.17% | -3.17% | -4.19% | -3.68% | -4.12% | -0.25% | -2.12% | -0.73% | -0.31% |
| EBITDA Growth % | - | -1.51% | -1.22% | -0.8% | -0.22% | 0.71% | -0.83% | 0.33% | 0.39% |
| D&A (Non-Cash Add-back) | 640K | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M |
| EBIT | -8.26M | -21.86M | -46.04M | -92.69M | -109.01M | -30.47M | -71.8M | -40.3M | 8.95M |
| Net Interest Income | 0 | 872K | 1.88M | 4.08M | 822K | 76K | 2.36M | 5.46M | 4.98M |
| Interest Income | 570K | 872K | 1.88M | 4.27M | 822K | 208K | 3.47M | 7.69M | 6.76M |
| Interest Expense | 0 | 0 | 0 | 182K | 0 | 132K | 1.11M | 2.23M | 1.78M |
| Other Income/Expense | 572K | 872K | 1.88M | -5.67M | 822K | 8.77M | -10.6M | 1.21M | 33.33M |
| Pretax Income | -8.26M | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -72.91M | -42.53M | 7.17M |
| Pretax Margin % | -1.18% | -3.25% | -4.23% | -4.18% | -4.49% | -0.26% | -2.9% | -0.87% | 0.1% |
| Income Tax | -5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.53% | 1.44% | 1% |
| Net Income | -8.25M | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -111.64M | -61.32M | 7.17M |
| Net Margin % | -1.18% | -3.25% | -4.23% | -4.18% | -4.49% | -0.26% | -4.45% | -1.26% | 0.1% |
| Net Income Growth % | - | -1.56% | -1.18% | -1.02% | -0.17% | 0.72% | -2.65% | 0.45% | 1.12% |
| Net Income (Continuing) | -8.25M | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -72.91M | -42.53M | 7.17M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | -38.73M | -18.79M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.49 | -18.81 | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.04 |
| EPS Growth % | - | -37.39% | -0.5% | -1.11% | -0.06% | 0.75% | -1.44% | 0.58% | 1.07% |
| EPS (Basic) | -0.49 | -18.81 | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.05 |
| Diluted Shares Outstanding | 16.74M | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.88M |
| Basic Shares Outstanding | 16.74M | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.83M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 94.4M | 64.33M | 115.67M | 193.67M | 105.56M | 161.75M | 199.1M | 136.36M | 94.99M |
| Cash & Short-Term Investments | 93.42M | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 86.31M |
| Cash Only | 93.42M | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 85.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 413K |
| Accounts Receivable | 386K | 22K | 523K | 965K | 10M | 488K | 720K | 12.8M | 1.7M |
| Days Sales Outstanding | 20.08 | 1.24 | 17.54 | 15.84 | 150.3 | 1.54 | 10.47 | 95.87 | 9.02 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 70K | 3.05M | 2.32M | 4K | 169K | 2.78M | 906K | 538K |
| Total Non-Current Assets | 4.01M | 8.35M | 22.93M | 41.56M | 44.59M | 49.74M | 39.06M | 23.42M | 41.4M |
| Property, Plant & Equipment | 3.54M | 8.14M | 21.15M | 39.57M | 41.5M | 29.33M | 13.78M | 14.6M | 10.18M |
| Fixed Asset Turnover | 1.98x | 0.80x | 0.51x | 0.56x | 0.59x | 3.94x | 1.82x | 3.34x | 6.75x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 90K | 1.47M | 1.43M | 1.37M | 2.05M | 731K | 400K | 622K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 6.84M | 4.75M | 3.21M | 3.21M |
| Other Non-Current Assets | 468K | 124K | 312K | 558K | 1.72M | 11.52M | 19.81M | 5.21M | 27.39M |
| Total Assets | 98.41M | 72.68M | 138.6M | 235.23M | 150.16M | 211.5M | 238.17M | 159.78M | 136.39M |
| Asset Turnover | 0.07x | 0.09x | 0.08x | 0.09x | 0.16x | 0.55x | 0.11x | 0.30x | 0.50x |
| Asset Growth % | - | -0.26% | 0.91% | 0.7% | -0.36% | 0.41% | 0.13% | -0.33% | -0.15% |
| Total Current Liabilities | 8.34M | 9.2M | 14.07M | 26.93M | 42.83M | 35.98M | 59.66M | 49.99M | 14.98M |
| Accounts Payable | 1.29M | 1.81M | 2.22M | 2.04M | 792K | 1.14M | 653K | 2.97M | 1.31M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.41M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 845K | 590K | 2.46M | 6.01M | 6.6M | 7.74M | 9.31M | 9.88M | 7.38M |
| Current Ratio | 11.32x | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x |
| Quick Ratio | 11.32x | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 94.82M | 89.85M | 84.56M | 69.99M | 62.9M | 84.35M | 118.07M | 90.93M | 65.02M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.48M | 22.22M | 0 | 22.32M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 8.59M | 4.81M | 1.06M | 7.72M | 6.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 433K | 1.25M | 1.76M | 4.09M | 392K | 44K | 1.92M | 128K | 2.99M |
| Total Liabilities | 103.16M | 99.05M | 98.64M | 96.92M | 105.73M | 120.33M | 177.74M | 140.92M | 80M |
| Total Debt | 0 | 0 | 0 | 0 | 10.52M | 9.11M | 24.96M | 31.27M | 30.05M |
| Net Debt | -93.42M | -62.8M | -103.19M | -180.89M | -79.28M | -134.55M | -164.62M | -85.41M | -55.85M |
| Debt / Equity | - | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -479.14x | - | -298.30x | -56.08x | -19.61x | -14.68x |
| Total Equity | -4.75M | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M |
| Equity Growth % | - | -4.55% | 2.52% | 2.46% | -0.68% | 1.05% | -0.34% | -0.69% | 1.99% |
| Book Value per Share | -0.28 | -23.51 | 24.45 | 98.80 | 25.61 | 46.60 | 20.63 | 4.91 | 8.19 |
| Total Shareholders' Equity | -4.75M | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K |
| Retained Earnings | -18.01M | -39.11M | -85.19M | -177.07M | -286.07M | -316.68M | -428.31M | -489.63M | -482.46M |
| Treasury Stock | 0 | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K |
| Accumulated OCI | 0 | -3.19M | -5.48M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 92.27M | -24.17M | -51.72M | -73.64M | -87.39M | -10.85M | -45.75M | -84.11M | -58.45M |
| Operating CF Margin % | 13.15% | -3.73% | -4.75% | -3.31% | -3.6% | -0.09% | -1.82% | -1.73% | -0.85% |
| Operating CF Growth % | - | -1.26% | -1.14% | -0.42% | -0.19% | 0.88% | -3.22% | -0.84% | 0.31% |
| Net Income | -8.25M | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -111.64M | -61.32M | 7.17M |
| Depreciation & Amortization | 640K | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M |
| Stock-Based Compensation | 0 | 419K | 2.45M | 0 | 13.79M | 16.51M | 19.2M | 14.04M | 12.6M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.37M | 174K | 14K | 16.28M | 35K | -26.55M | 13.57M | -3.6M | -28.79M |
| Working Capital Changes | 99.72M | -5.09M | -10.51M | -2.36M | -2.01M | 19.58M | 24.11M | -41.49M | -54M |
| Change in Receivables | 0 | 0 | -523K | -441K | -9.04M | 9.51M | -232K | -181K | 10.42M |
| Change in Inventory | 0 | 0 | -5.95M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 82K | 864K | -673K | 667K | -1.46M | 867K | 153K | 1.51M | -2.1M |
| Cash from Investing | -2.08M | -5.51M | -15.66M | -24.67M | -5.03M | -5.8M | -3.32M | 5.83M | -215K |
| Capital Expenditures | -2.08M | -5.57M | -15.68M | -24.67M | -5.03M | -5.05M | -3.32M | -2.28M | -250K |
| CapEx % of Revenue | 0.3% | 0.86% | 1.44% | 1.11% | 0.21% | 0.04% | 0.13% | 0.05% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 50K | 15K | 0 | 0 | -750K | 0 | 107K | -25K |
| Cash from Financing | -12.38M | -937K | 107.78M | 176M | 1.33M | 70.52M | 94.98M | 5.39M | 50.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -12.43M | 15K | -1.97M | 0 | 1.33M | 7.57M | 835K | 401K | 249K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 90.2M | -29.73M | -67.4M | -98.3M | -92.42M | -16.66M | -49.07M | -86.39M | -58.7M |
| FCF Margin % | 12.86% | -4.59% | -6.19% | -4.42% | -3.81% | -0.14% | -1.96% | -1.77% | -0.85% |
| FCF Growth % | - | -1.33% | -1.27% | -0.46% | 0.06% | 0.82% | -1.95% | -0.76% | 0.32% |
| FCF per Share | 5.39 | -26.51 | -41.24 | -70.22 | -53.28 | -8.51 | -16.75 | -22.49 | -8.53 |
| FCF Conversion (FCF/Net Income) | -11.18x | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 68K | 824K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -677.46% | -104.2% | -119.3% | -45.14% | -147.28% | -154.66% | 19.05% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -117.62% | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | 10.43% |
| Debt / Equity | - | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x |
| Interest Coverage | - | - | - | -479.14x | - | -298.30x | -56.08x | -19.61x | -14.68x |
| FCF Conversion | -11.18x | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x |
| Revenue Growth | - | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% |
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Therapeutics | 20.63M | 21.86M | 111.72M |
| Therapeutics Growth | - | 5.97% | 411.01% |
| Food | 1.61M | 2.42M | 3.81M |
| Food Growth | - | 50.81% | 57.14% |
Precision BioSciences, Inc. (DTIL) has a price-to-earnings (P/E) ratio of 3.8x. This may indicate the stock is undervalued or faces growth challenges.
Precision BioSciences, Inc. (DTIL) reported $0.7M in revenue for fiscal year 2024. This represents a 90% decrease from $7.0M in 2016.
Precision BioSciences, Inc. (DTIL) grew revenue by 41.0% over the past year. This is strong growth.
Precision BioSciences, Inc. (DTIL) reported a net loss of $83.6M for fiscal year 2024.
Precision BioSciences, Inc. (DTIL) has a return on equity (ROE) of 19.0%. This is reasonable for most industries.
Precision BioSciences, Inc. (DTIL) had negative free cash flow of $73.7M in fiscal year 2024, likely due to heavy capital investments.